Decreased BDNF/TrkB agonist-dependent GR phosphorylation may contribute to comorbidity of MetS along with psychiatric disorders like anxiety and depression, making the BDNF/TrkB pathway a target for potential therapeutic recovery [51]. This evidence concerns the gene NR3C1 and depressive symptom measurement.